Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PinnacleXon Apr 12, 2021 2:03pm
123 Views
Post# 32978458

RE:RE:Nothing

RE:RE:Nothing
SPCEO1 wrote: Last year on the VM news, we had around 2 million shares trade pre-market and the stock was up  50%. This year, the research showed a melonoma tumor was vanquished in 21 days but the robot traders were apparently not plugged in this morning so we traded up a few pennies on 12,000 shares in the pre-market.  

What a bizarre stock! 

So far, none of the analysts have commented on the AACR news (Canaccord put out a perfunctory blurb when they announced the abstracts were available back in March).

It sure seems like the only people investors attention to TH are the people who are part of this message board. And we already own the stock in a substantial way, largely after doing the homework to convince ourselves of its value by ourself. So, yes, we have a IR problem as has been pointed out endlessly, but with no apparent action being taken to remedy the sad state of affairs as best we can see. 

longterm56 wrote: A big yawn in pre-market trading. Another great achievement by the IR people. Not just anytime can keep the share price smothered after such great news. Truly amazing.




Bizarre is an understatment, its unheard of. This should be double on that news alone, WTF a tumor gone using your treatment in 21 days!!!! and NOTHING!  what makes it even more so its on the NYSE and it doesnt get picked up there aswell. 

<< Previous
Bullboard Posts
Next >>